Key Takeaways The latest outcomes of the effects of COVID19 on the delay of new product launch Can Price Transparency contribute to more affordable patient access to medicines? Reaching a better integration of regulatory pathways A look into the personalized reimbursement system Early Payer Engagement Equal access and multi-indication medicines
